Compare CoreWeave (CRWV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CoreWeave vs Novavax Inc — how do they compare? CoreWeave trades at $82.37 (market cap $44.99B), while Novavax Inc trades at $12.7 (market cap $1.82B). The key difference: CoreWeave is far larger — about 24.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, CoreWeave nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 7 Days and Novavax Inc for 59 Days on average.
| CRWV | NVAX | |
|---|---|---|
Market Cap | $44.99B | $1.82B |
Volume | 41,993,776 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $143.08 | $12.56 |
52-Week Low | $60.82 | $6.22 |
Typical Hold Time | 7 Days | 59 Days |
Enterprise Value | $91.06B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRWV trades at $82.08, down 7.2% amid a broader AI stock sell-off. The technical picture is bearish, with price below key resistance levels. Fundamentally, the company shows strong revenue growth but deep losses, with a net income margin of -25.4% in 2026. A massive $104 billion backlog signals high demand, yet expansion requires significant debt and equity financing, increasing financial risk.
The outlook is polarized: high growth potential from AI infrastructure demand contrasts with substantial execution and financial risks. Analyst consensus is bullish with a $147.57 price target, but investors face volatility from debt-funded expansion and competitive pressures. The stock's trajectory hinges on converting its backlog to profitable revenue.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CoreWeave
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
